DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER (" Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") 1 and 2 studies and new in vitro data of dalbavancin, further characterizing the effect of the investigational treatment against Gram-positive bacteria. In the two randomized, double-blind clinical studies, dalbavancin was shown to be non-inferior to the comparator regimen, vancomycin with an option to switch to oral linezolid, in treating acute bacterial skin and skin structure infections (ABSSSI). i, ii In both studies, dalbavancin met its primary and secondary endpoints. Further, recipients in the dalbavancin arms of the studies had fewer treatment emergent adverse events than those in the comparator arms. i, ii The in vitro data showed activity against Staphylococcus aureus strains, including methicillin-resistant strains (MRSA), recovered from patients with osteomyelitis-related wounds. iii The data were presented in three separate posters at the 53 rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, CO.
Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results And New In Vitro Data On Dalbavancin At ICAAC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts